CR20190400A - Formulaciones de anticuerpo monoclonal anti-vrs - Google Patents

Formulaciones de anticuerpo monoclonal anti-vrs

Info

Publication number
CR20190400A
CR20190400A CR20190400A CR20190400A CR20190400A CR 20190400 A CR20190400 A CR 20190400A CR 20190400 A CR20190400 A CR 20190400A CR 20190400 A CR20190400 A CR 20190400A CR 20190400 A CR20190400 A CR 20190400A
Authority
CR
Costa Rica
Prior art keywords
monoclonal antibody
antibody formulation
rsv monoclonal
formulation
present
Prior art date
Application number
CR20190400A
Other languages
English (en)
Spanish (es)
Inventor
Deborah Goldberg
Brian Lobo
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CR20190400A publication Critical patent/CR20190400A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CR20190400A 2017-03-01 2018-02-28 Formulaciones de anticuerpo monoclonal anti-vrs CR20190400A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762465379P 2017-03-01 2017-03-01
PCT/US2018/020264 WO2018160722A1 (en) 2017-03-01 2018-02-28 Anti-rsv monoclonal antibody formulation

Publications (1)

Publication Number Publication Date
CR20190400A true CR20190400A (es) 2019-12-03

Family

ID=61903153

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20190400A CR20190400A (es) 2017-03-01 2018-02-28 Formulaciones de anticuerpo monoclonal anti-vrs

Country Status (24)

Country Link
US (4) US10774133B2 (enExample)
EP (1) EP3589648A4 (enExample)
JP (2) JP7046088B2 (enExample)
KR (2) KR102668158B1 (enExample)
CN (3) CN110418803B (enExample)
AR (1) AR111083A1 (enExample)
AU (2) AU2018227502B2 (enExample)
BR (1) BR112019017755A2 (enExample)
CA (1) CA3051864A1 (enExample)
CL (1) CL2019002478A1 (enExample)
CO (1) CO2019009034A2 (enExample)
CR (1) CR20190400A (enExample)
EA (1) EA201991701A1 (enExample)
EC (1) ECSP19062769A (enExample)
GB (1) GB2564175B (enExample)
IL (2) IL268202B2 (enExample)
MX (1) MX2019010408A (enExample)
MY (1) MY206022A (enExample)
PH (1) PH12019501979A1 (enExample)
SG (1) SG11201906853QA (enExample)
TW (2) TWI761453B (enExample)
UA (1) UA128450C2 (enExample)
WO (1) WO2018160722A1 (enExample)
ZA (1) ZA202006797B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374517B (es) 2014-01-15 2025-03-06 Medimmune Ltd Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.
EP3383435A4 (en) * 2015-11-30 2019-07-10 Medimmune, LLC OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
KR102589598B1 (ko) * 2017-03-01 2023-10-13 메디뮨 리미티드 단클론 항체의 제형
TWI761453B (zh) 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
US11845798B2 (en) 2017-05-02 2023-12-19 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2020081408A1 (en) * 2018-10-18 2020-04-23 Merck Sharp & Dohme Corp. Formulations of anti-rsv antibodies and methods of use thereof
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
EP3956351A1 (en) * 2019-04-18 2022-02-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Biological and synthetic molecules inhibiting respiratory syncytial virus infection
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies
ES2973425T3 (es) 2020-03-26 2024-06-20 Univ Vanderbilt Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del síndrome respiratorio agudo grave (sars-cov-2)
CN116234576A (zh) * 2020-07-31 2023-06-06 阿拉玛布治疗学股份有限公司 抗-连接蛋白抗体制剂
CN115960214A (zh) * 2021-10-12 2023-04-14 中国科学院分子细胞科学卓越创新中心 中和呼吸道合胞病毒的全人抗体的设计及应用
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
CN119264248A (zh) * 2022-07-22 2025-01-07 北京智仁美博生物科技有限公司 抗呼吸道合胞病毒中和性抗体及其用途
CN119998314A (zh) * 2022-12-08 2025-05-13 长春百克生物科技股份公司 特异性结合rsv的抗体

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
AU7240096A (en) 1995-09-18 1997-04-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Neutralizing monoclonal antibodies to respiratory syncytial virus
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
ATE556591T1 (de) 2001-11-08 2012-05-15 Abbott Biotherapeutics Corp Stabile pharmazeutische flüssigformulierung von igg-antikörpern
AU2013201261B2 (en) * 2002-06-14 2016-06-23 Medimmune, Llc Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
HRP20050934B1 (hr) * 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
TW200636064A (en) 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP2639242A3 (en) * 2006-03-06 2013-10-16 MedImmune, Inc. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
RU2011122615A (ru) 2008-11-05 2012-12-20 Мерк Шарп Энд Домэ Корп. Живой аттенуированный респираторно-синцитиальный вирус
US20120121580A1 (en) * 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
BR112012008173B1 (pt) 2009-10-06 2021-12-07 Medimmune Ltd Anticorpo monoclonal humano recombinante, sintético ou isolado ou uma parte funcional do mesmo que se liga especificamente à proteína f do vírus sincicial respiratório, sequência de ácido nucleico isolada ou um equivalente funcional da mesma, vetor, combinação, composição farmacêutica, usos dos mesmos e método para produzir um anticorpo ou parte funcional do mesmo
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CL2011003002A1 (es) 2011-11-25 2012-05-25 Univ Pontificia Catolica Chile Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
JP6265970B2 (ja) * 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
SMT202000145T1 (it) 2013-02-01 2020-05-08 Medimmune Llc Epitopi di proteina f di virus sinciziale respiratorio
MX374517B (es) * 2014-01-15 2025-03-06 Medimmune Ltd Anticuerpos especificos del virus respiratorio sincitial (vrs) y partes funcionales de los mismos.
BR112017007393A2 (pt) 2014-10-18 2017-12-19 Pfizer composições de anticorpo anti-il-7r
CA2991002C (en) * 2015-07-07 2023-11-28 Janssen Vaccines & Prevention B.V. Vaccine against rsv
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
KR102589598B1 (ko) * 2017-03-01 2023-10-13 메디뮨 리미티드 단클론 항체의 제형
TWI761453B (zh) * 2017-03-01 2022-04-21 英商梅迪繆思有限公司 抗rsv單株抗體配製物
US12024553B2 (en) * 2019-04-30 2024-07-02 Medimmune Limited Dosage regimens for and compositions including anti-RSV antibodies

Also Published As

Publication number Publication date
KR20220020420A (ko) 2022-02-18
PH12019501979A1 (en) 2020-06-29
AU2018227502A1 (en) 2019-08-15
MY206022A (en) 2024-11-25
EP3589648A4 (en) 2020-12-23
US11286294B2 (en) 2022-03-29
US20230399383A1 (en) 2023-12-14
AU2022263564B2 (en) 2025-05-22
EP3589648A1 (en) 2020-01-08
CN116059343A (zh) 2023-05-05
CL2019002478A1 (es) 2020-01-24
IL268202A (en) 2019-09-26
JP7046088B2 (ja) 2022-04-01
GB2564175B (en) 2021-12-08
CN117982637A (zh) 2024-05-07
JP7446356B2 (ja) 2024-03-08
AR111083A1 (es) 2019-05-29
CO2019009034A2 (es) 2019-08-30
ZA202006797B (en) 2023-03-29
US11667698B2 (en) 2023-06-06
ECSP19062769A (es) 2019-09-30
GB2564175A (en) 2019-01-09
JP2020509031A (ja) 2020-03-26
NZ755790A (en) 2024-04-26
US10774133B2 (en) 2020-09-15
WO2018160722A1 (en) 2018-09-07
IL268202B2 (en) 2024-10-01
AU2022263564A1 (en) 2022-12-15
EA201991701A1 (ru) 2020-03-04
KR102359181B1 (ko) 2022-02-08
TW201840334A (zh) 2018-11-16
UA128450C2 (uk) 2024-07-17
TW202228779A (zh) 2022-08-01
CA3051864A1 (en) 2018-09-07
IL312499A (en) 2024-07-01
JP2022095697A (ja) 2022-06-28
IL268202B1 (en) 2024-06-01
CN110418803A (zh) 2019-11-05
TWI761453B (zh) 2022-04-21
BR112019017755A2 (pt) 2020-04-07
US20180251526A1 (en) 2018-09-06
GB201802974D0 (en) 2018-04-11
KR102668158B1 (ko) 2024-05-23
SG11201906853QA (en) 2019-09-27
KR20190125318A (ko) 2019-11-06
CN110418803B (zh) 2024-01-19
US20200339667A1 (en) 2020-10-29
US20210317191A1 (en) 2021-10-14
MX2019010408A (es) 2019-12-19
AU2018227502B2 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
ECSP19062769A (es) Formulación de anticuerpo monoclonal anti-vrs
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
AR108240A1 (es) Formulaciones que contienen anticuerpos
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
MX387451B (es) Formulacion liquida que comprende un compuesto neutralizante de gm-csf.
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
NZ719036A (en) Anti-pdl1 antibody formulations
NZ743964A (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
CL2018000226A1 (es) Mezcla de péptidos (divisional solicitud 201601405)
BR112017003419A2 (pt) formulação de anticorpo anti-il-4r-alfa estável
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
PE20191796A1 (es) Composicion farmaceutica de clorhidrato de s-ketamina
GT201100181A (es) "inhibidores de proteina cinasa"
PE20191242A1 (es) Formulaciones de anticuerpo y metodos
AR098168A1 (es) Formulación estable de insulina glulisina
PE20160012A1 (es) Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
PE20191476A1 (es) Nueva formulacion estable de anticuerpos anti-fxia
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
PE20150190A1 (es) Formulacion farmaceutica
EA202090945A1 (ru) Анти-msln-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
BR112019023981A2 (pt) injeção de octreotida
AR092325A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4 y kit